Are You in Control of Your Data

FDA Clearance of New Fungal Infection Diagnostic Test

Associates of Cape Cod, Inc. have announced that the FDA has cleared Glucatell®, a serological assay that is intended for the qualitative detection of beta-glucan in the serum of patients with symptoms of, or medical conditions predisposing the patient to, invasive fungal infection and as an aid in the diagnosis of deep seated mycoses and fungemias.

Glucatell®, a serum test, measures (1,3)-beta-D-glucan, a fungal wall compound that is shed into the blood during fungal infections. Glucatell® is sensitive to a few trillionths of a gram of (1,3)-beta-D-glucan.

In a recent study, Glucatell(R) use resulted in a median of 12 days advance indication of fungal infection, as compared with conventional diagnostic procedures.

Associates of Cape Cod, Inc. will be offering Glucatell® in kit form to reference laboratories, hospital laboratories and as a service in its East Falmouth, Massachusetts CLIA laboratory.


NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source: Associates of Cape Cod, Inc. View latest company information

Posted: June 14, 2004
Request Information
[will open your email client]

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed